Colistin-resistant Enterobacteriaceae infections: clinical and molecular characterization and analysis of in vitro synergy
Carregando...
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
CARRILLHO, Claudia M. D. de Maio
URBANO, Mariana R.
PEROZIN, Jamile S.
Citação
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, v.87, n.3, p.253-257, 2017
Resumo
We described 27 polyclonal colistin-resistant Enterobacteriaceae (MIC 4-16 mu g/mL) infections (12 pneumonia, 12 urinary tract infection (UTI), two Bacteremia, and one skin/soft tissue infection) in which 74% harbored KPC. The isolates were polyclonal, 6 STs were identified and the colistin resistance was due to chromosome mutations. Eight patients with UTI received monotherapy, and combination therapy was given to 19 patients. Overall mortality was 37%. In vitro synergy using time-kill assay was observed in 14 of 19 (74%) isolates tested; the synergistic effect was observed for almost all isolates for the combination of three drugs: colistin, amikacin, and tigecycline. The Kaplan-Meier survival curve showed no significant difference comparing combination therapy with 2, 3, or more drugs and risk factors associated with death were dialysis and shock. These findings reinforce the fact that colistin in combination with other classes of drugs can be useful in treating infections caused by colistin-resistant CRE.
Palavras-chave
Colistin-resistance, Enterobacteriaceae, Synergy, Treatment
Referências
- CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
- Chen L, 2014, ANTIMICROB AGENTS CH, V58, P2871, DOI 10.1128/AAC.00120-14
- CLSI, 2011, M100S21 CLSI
- Falcone M, 2016, CLIN MICROBIOL INFEC
- Gaibani P, 2014, J ANTIMICROB CHEMOTH, V69, P1856, DOI 10.1093/jac/dku065
- Ji SJ, 2015, INT J INFECT DIS, V38, P108, DOI 10.1016/j.ijid.2015.07.024
- Kontopidou F, 2011, CLIN MICROBIOL INFEC, V17, pE9, DOI 10.1111/j.1469-0691.2011.03649.x
- Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
- Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7
- Martins WMBS, 2015, DIAGN MICR INFEC DIS, V83, P375, DOI 10.1016/j.diagmicrobio.2015.09.003
- Munoz-Price LS, 2013, LANCET INFECT DIS, V13, P785, DOI 10.1016/S1473-3099(13)70190-7
- Olaitan AO, 2015, INT J ANTIMICROB AG, V46, P354, DOI 10.1016/j.ijantimicag.2015.06.003
- Petersen PJ, 2006, J ANTIMICROB CHEMOTH, V57, P573, DOI 10.1093/jac/dki477
- Poirel L, 2016, J ANTIMICROB CHEMOTH, V71, P156, DOI 10.1093/jac/dkv294
- Seki LM, 2011, DIAGN MICR INFEC DIS, V70, P274, DOI 10.1016/j.diagmicrobio.2011.01.006